Equities analysts expect that Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) will post sales of $44.00 million for the current quarter, Zacks reports. Two analysts have provided estimates for Vanda Pharmaceuticals’ earnings. Vanda Pharmaceuticals posted sales of $38.24 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 15.1%. The business is expected to issue its next earnings results on Wednesday, February 21st.

On average, analysts expect that Vanda Pharmaceuticals will report full year sales of $44.00 million for the current financial year, with estimates ranging from $164.80 million to $165.70 million. For the next financial year, analysts forecast that the company will report sales of $204.50 million per share, with estimates ranging from $193.00 million to $214.70 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). The firm had revenue of $41.30 million for the quarter, compared to analysts’ expectations of $43.90 million. Vanda Pharmaceuticals had a negative return on equity of 10.99% and a negative net margin of 9.01%. The company’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same quarter last year, the business earned ($0.01) EPS.

Several research firms have weighed in on VNDA. Oppenheimer reiterated a “buy” rating and set a $25.00 price objective on shares of Vanda Pharmaceuticals in a research report on Sunday, November 12th. ValuEngine cut Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Zacks Investment Research cut Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 26th. Finally, Piper Jaffray Companies set a $26.00 price objective on Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, October 19th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $21.50.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Rice Hall James & Associates LLC increased its position in shares of Vanda Pharmaceuticals by 1.0% in the second quarter. Rice Hall James & Associates LLC now owns 27,903 shares of the biopharmaceutical company’s stock worth $455,000 after purchasing an additional 279 shares during the period. California Public Employees Retirement System increased its position in shares of Vanda Pharmaceuticals by 3.8% in the second quarter. California Public Employees Retirement System now owns 59,600 shares of the biopharmaceutical company’s stock worth $971,000 after purchasing an additional 2,200 shares during the period. Legal & General Group Plc increased its position in shares of Vanda Pharmaceuticals by 37.4% in the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 3,022 shares during the period. Bank of New York Mellon Corp increased its position in shares of Vanda Pharmaceuticals by 1.7% in the third quarter. Bank of New York Mellon Corp now owns 199,578 shares of the biopharmaceutical company’s stock worth $3,573,000 after purchasing an additional 3,305 shares during the period. Finally, Voya Investment Management LLC increased its position in shares of Vanda Pharmaceuticals by 29.7% in the second quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock worth $328,000 after purchasing an additional 4,605 shares during the period. Institutional investors own 88.45% of the company’s stock.

Vanda Pharmaceuticals (NASDAQ:VNDA) opened at $13.85 on Tuesday. Vanda Pharmaceuticals has a 12-month low of $11.90 and a 12-month high of $18.99.

TRADEMARK VIOLATION NOTICE: This piece was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/12/vanda-pharmaceuticals-inc-vnda-expected-to-announce-quarterly-sales-of-44-00-million.html.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.